Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 169 entries
Sorted by: Best Match Show Resources per page
Photothermal initiation of hybrid organic/inorganic metastable interstitial composites: synergistic effects on the dynamics of energy release.

The journal of physical chemistry. A

Mileham ML, Park CD, van de Burgt LJ, Kramer MP, Stiegman AE.
PMID: 18942803
J Phys Chem A. 2008 Dec 11;112(49):12568-71. doi: 10.1021/jp8064344.

The organic high-energy material pentaerythritol tetranitrate (PETN) was incorporated at low concentrations into Al (100 nm)/Fe(2)O(3) metastable intersitital composites (MIC) to form a hybrid organic/inorganic high-energy material. Studies of the dynamics of energy release were carried out by initiating...

Cite
Mileham ML, Park CD, van de Burgt LJ, et al. Photothermal initiation of hybrid organic/inorganic metastable interstitial composites: synergistic effects on the dynamics of energy release. J Phys Chem A. 2008;112(49):12568-71doi: 10.1021/jp8064344.
Mileham, M. L., Park, C. D., van de Burgt, L. J., Kramer, M. P., & Stiegman, A. E. (2008). Photothermal initiation of hybrid organic/inorganic metastable interstitial composites: synergistic effects on the dynamics of energy release. The journal of physical chemistry. A, 112(49), 12568-71. https://doi.org/10.1021/jp8064344
Mileham, Melissa L, et al. "Photothermal initiation of hybrid organic/inorganic metastable interstitial composites: synergistic effects on the dynamics of energy release." The journal of physical chemistry. A vol. 112,49 (2008): 12568-71. doi: https://doi.org/10.1021/jp8064344
Mileham ML, Park CD, van de Burgt LJ, Kramer MP, Stiegman AE. Photothermal initiation of hybrid organic/inorganic metastable interstitial composites: synergistic effects on the dynamics of energy release. J Phys Chem A. 2008 Dec 11;112(49):12568-71. doi: 10.1021/jp8064344. PMID: 18942803.
Copy Download .nbib Format: NLM
Nelfinavir treatment of adenoid cystic carcinoma: A case report.

Practical radiation oncology

de la Garza GO, Ismail AF, Anderson CM, Wilke WW, Milhem MM, Hoffman HT, Buatti JM.
PMID: 24674175
Pract Radiat Oncol. 2012 Oct-Dec;2(4):e129-e132. doi: 10.1016/j.prro.2011.09.003. Epub 2011 Oct 26.

No abstract available.

Cite
de la Garza GO, Ismail AF, Anderson CM, et al. Nelfinavir treatment of adenoid cystic carcinoma: A case report. Pract Radiat Oncol. 2011;2(4):e129-e132doi: 10.1016/j.prro.2011.09.003.
de la Garza, G. O., Ismail, A. F., Anderson, C. M., Wilke, W. W., Milhem, M. M., Hoffman, H. T., & Buatti, J. M. (2012). Nelfinavir treatment of adenoid cystic carcinoma: A case report. Practical radiation oncology, 2(4), e129-e132. https://doi.org/10.1016/j.prro.2011.09.003
de la Garza, Gabriel O, et al. "Nelfinavir treatment of adenoid cystic carcinoma: A case report." Practical radiation oncology vol. 2,4 (2012): e129-e132. doi: https://doi.org/10.1016/j.prro.2011.09.003
de la Garza GO, Ismail AF, Anderson CM, Wilke WW, Milhem MM, Hoffman HT, Buatti JM. Nelfinavir treatment of adenoid cystic carcinoma: A case report. Pract Radiat Oncol. 2012 Oct-Dec;2(4):e129-e132. doi: 10.1016/j.prro.2011.09.003. Epub 2011 Oct 26. PMID: 24674175.
Copy Download .nbib Format: NLM
A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.

Cancers

Monga V, Swami U, Tanas M, Bossler A, Mott SL, Smith BJ, Milhem M.
PMID: 29462961
Cancers (Basel). 2018 Feb 17;10(2). doi: 10.3390/cancers10020053.

Epigenetic events and genetic alterations under the control of the tumor microenvironment potentially mediate tumor induced angiogenesis involved in soft tissue sarcoma (STS) metastasis. Addition of antiangiogenic agent, such as bevacizumab, to standard chemotherapy in treatment of sarcoma has...

Cite
Monga V, Swami U, Tanas M, et al. A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers (Basel). 2018;10(2)doi: 10.3390/cancers10020053.
Monga, V., Swami, U., Tanas, M., Bossler, A., Mott, S. L., Smith, B. J., & Milhem, M. (2018). A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers, 10(2), . https://doi.org/10.3390/cancers10020053
Monga, Varun, et al. "A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas." Cancers vol. 10,2 (2018). doi: https://doi.org/10.3390/cancers10020053
Monga V, Swami U, Tanas M, Bossler A, Mott SL, Smith BJ, Milhem M. A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers (Basel). 2018 Feb 17;10(2). doi: 10.3390/cancers10020053. PMID: 29462961; PMCID: PMC5836085.
Copy Download .nbib Format: NLM
Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

BMC cancer

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.
PMID: 29649990
BMC Cancer. 2018 Apr 12;18(1):413. doi: 10.1186/s12885-018-4200-5.

It has been highlighted that in the original manuscript [1] Table S3 'An example of the predictive computational modeling process. Specific details on an annexure section of the PD-L1 pathway show the step-by-step reactions, mechanisms, and reaction equations that...

Cite
Brogden KA, Parashar D, Hallier AR, et al. Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer. 2018;18(1):413doi: 10.1186/s12885-018-4200-5.
Brogden, K. A., Parashar, D., Hallier, A. R., Braun, T., Qian, F., Rizvi, N. A., Bossler, A. D., Milhem, M. M., Chan, T. A., Abbasi, T., & Vali, S. (2018). Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC cancer, 18(1), 413. https://doi.org/10.1186/s12885-018-4200-5
Brogden, Kim A, et al. "Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy." BMC cancer vol. 18,1 (2018): 413. doi: https://doi.org/10.1186/s12885-018-4200-5
Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S. Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer. 2018 Apr 12;18(1):413. doi: 10.1186/s12885-018-4200-5. PMID: 29649990; PMCID: PMC5898039.
Copy Download .nbib Format: NLM
Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.

Oncotarget

Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M.
PMID: 29179510
Oncotarget. 2017 Sep 26;8(51):89182-89193. doi: 10.18632/oncotarget.21269. eCollection 2017 Oct 24.

INTRODUCTION: Epigenetic modifications play an important role in progression and development of resistance in EXPERIMENTAL DESIGN: The study employed 3+3 dose escalation combining subcutaneous decitabine at different doses and schedules (4 cohorts) with the standard oral dose of vemurafenib...

Cite
Zakharia Y, Monga V, Swami U, et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget. 2017;8(51):89182-89193doi: 10.18632/oncotarget.21269.
Zakharia, Y., Monga, V., Swami, U., Bossler, A. D., Freesmeier, M., Frees, M., Khan, M., Frydenlund, N., Srikantha, R., Vanneste, M., Henry, M., & Milhem, M. (2017). Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget, 8(51), 89182-89193. https://doi.org/10.18632/oncotarget.21269
Zakharia, Yousef, et al. "Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study." Oncotarget vol. 8,51 (2017): 89182-89193. doi: https://doi.org/10.18632/oncotarget.21269
Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget. 2017 Sep 26;8(51):89182-89193. doi: 10.18632/oncotarget.21269. eCollection 2017 Oct 24. PMID: 29179510; PMCID: PMC5687680.
Copy Download .nbib Format: NLM
Meckel-Gruber syndrome: A rare and lethal anomaly.

Sudanese journal of paediatrics

Kheir AE, Imam A, Omer IM, Hassan IM, Elamin SA, Awadalla EA, Gadalla MH, Hamdoon TA.
PMID: 27493335
Sudan J Paediatr. 2012;12(1):93-6.

Meckel-Gruber syndrome is a rare and lethal autosomal recessive disorder characterized by occipital encephalocele, postaxial polydactyly and bilateral dysplastic cystic kidneys. It can be associated with many other conditions. Antenatal ultrasound examination establishes the diagnosis by identifying at least...

Cite
Kheir AE, Imam A, Omer IM, et al. Meckel-Gruber syndrome: A rare and lethal anomaly. Sudan J Paediatr. 2012;12(1):93-6
Kheir, A. E., Imam, A., Omer, I. M., Hassan, I. M., Elamin, S. A., Awadalla, E. A., Gadalla, M. H., & Hamdoon, T. A. (2012). Meckel-Gruber syndrome: A rare and lethal anomaly. Sudanese journal of paediatrics, 12(1), 93-6.
Kheir, Abdelmoneim E M, et al. "Meckel-Gruber syndrome: A rare and lethal anomaly." Sudanese journal of paediatrics vol. 12,1 (2012): 93-6.
Kheir AE, Imam A, Omer IM, Hassan IM, Elamin SA, Awadalla EA, Gadalla MH, Hamdoon TA. Meckel-Gruber syndrome: A rare and lethal anomaly. Sudan J Paediatr. 2012;12(1):93-6. PMID: 27493335; PMCID: PMC4949827.
Copy Download .nbib Format: NLM
The Effects of Cocaine on Nonhuman Primate Brain Function Are Age Dependent.

Annals of the New York Academy of Sciences

Paule MG, Gillam MP, Morris P.
PMID: 29090798
Ann N Y Acad Sci. 1998 May;844(1):178-182. doi: 10.1111/j.1749-6632.1998.tb08232.x.

The effects of acute intravenous (i.v.) cocaine (COC) on several complex brain functions were studied in rhesus monkeys at 1.5, 3 and 10-11 years of age. Subjects performed several operant tasks (for food) that were used to model learning,...

Cite
Paule MG, Gillam MP, Morris P. The Effects of Cocaine on Nonhuman Primate Brain Function Are Age Dependent. Ann N Y Acad Sci. 1998;844(1):178-182doi: 10.1111/j.1749-6632.1998.tb08232.x.
Paule, M. G., Gillam, M. P., & Morris, P. (1998). The Effects of Cocaine on Nonhuman Primate Brain Function Are Age Dependent. Annals of the New York Academy of Sciences, 844(1), 178-182. https://doi.org/10.1111/j.1749-6632.1998.tb08232.x
Paule, Merle G, et al. "The Effects of Cocaine on Nonhuman Primate Brain Function Are Age Dependent." Annals of the New York Academy of Sciences vol. 844,1 (1998): 178-182. doi: https://doi.org/10.1111/j.1749-6632.1998.tb08232.x
Paule MG, Gillam MP, Morris P. The Effects of Cocaine on Nonhuman Primate Brain Function Are Age Dependent. Ann N Y Acad Sci. 1998 May;844(1):178-182. doi: 10.1111/j.1749-6632.1998.tb08232.x. PMID: 29090798.
Copy Download .nbib Format: NLM
Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine.

The Journal of clinical and aesthetic dermatology

Milam P, Berger M, Ramaswamy B, Reinbolt R, Wesolowski R, Kaffenberger BH.
PMID: 31531159
J Clin Aesthet Dermatol. 2019 Jul;12(7):23-26. Epub 2019 Jul 01.

No abstract available.

Cite
Milam P, Berger M, Ramaswamy B, et al. Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine. J Clin Aesthet Dermatol. 2019;12(7):23-26
Milam, P., Berger, M., Ramaswamy, B., Reinbolt, R., Wesolowski, R., & Kaffenberger, B. H. (2019). Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine. The Journal of clinical and aesthetic dermatology, 12(7), 23-26.
Milam, Philip, et al. "Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine." The Journal of clinical and aesthetic dermatology vol. 12,7 (2019): 23-26.
Milam P, Berger M, Ramaswamy B, Reinbolt R, Wesolowski R, Kaffenberger BH. Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine. J Clin Aesthet Dermatol. 2019 Jul;12(7):23-26. Epub 2019 Jul 01. PMID: 31531159; PMCID: PMC6715332.
Copy Download .nbib Format: NLM
Binding modes of CYP106A2 redox partners determine differences in progesterone hydroxylation product patterns.

Communications biology

Sagadin T, Riehm JL, Milhim M, Hutter MC, Bernhardt R.
PMID: 30271979
Commun Biol. 2018 Jul 30;1:99. doi: 10.1038/s42003-018-0104-9. eCollection 2018.

Natural redox partners of bacterial cytochrome P450s (P450s) are mostly unknown. Therefore, substrate conversions are performed with heterologous redox partners; in the case of CYP106A2 from

Cite
Sagadin T, Riehm JL, Milhim M, et al. Binding modes of CYP106A2 redox partners determine differences in progesterone hydroxylation product patterns. Commun Biol. 2018;1:99doi: 10.1038/s42003-018-0104-9.
Sagadin, T., Riehm, J. L., Milhim, M., Hutter, M. C., & Bernhardt, R. (2018). Binding modes of CYP106A2 redox partners determine differences in progesterone hydroxylation product patterns. Communications biology, 199. https://doi.org/10.1038/s42003-018-0104-9
Sagadin, Tanja, et al. "Binding modes of CYP106A2 redox partners determine differences in progesterone hydroxylation product patterns." Communications biology vol. 1 (2018): 99. doi: https://doi.org/10.1038/s42003-018-0104-9
Sagadin T, Riehm JL, Milhim M, Hutter MC, Bernhardt R. Binding modes of CYP106A2 redox partners determine differences in progesterone hydroxylation product patterns. Commun Biol. 2018 Jul 30;1:99. doi: 10.1038/s42003-018-0104-9. eCollection 2018. PMID: 30271979; PMCID: PMC6123783.
Copy Download .nbib Format: NLM
Clinical Perspective on Passive Audio Vocal Measurement in the Evaluation of Selective Mutism.

Frontiers in psychiatry

Xu HY, Stroud J, Jozanovic RK, Clucas J, Son JJ, Koo B, Schwarz J, Klein A, Busman R, Milham MP.
PMID: 30298025
Front Psychiatry. 2018 Sep 21;9:443. doi: 10.3389/fpsyt.2018.00443. eCollection 2018.

Selective Mutism (SM) is an anxiety disorder often diagnosed in early childhood and characterized by persistent failure to speak in certain social situations but not others. Diagnosing SM and monitoring treatment response can be quite complex, due in part...

Cite
Xu HY, Stroud J, Jozanovic RK, et al. Clinical Perspective on Passive Audio Vocal Measurement in the Evaluation of Selective Mutism. Front Psychiatry. 2018;9:443doi: 10.3389/fpsyt.2018.00443.
Xu, H. Y., Stroud, J., Jozanovic, R. K., Clucas, J., Son, J. J., Koo, B., Schwarz, J., Klein, A., Busman, R., & Milham, M. P. (2018). Clinical Perspective on Passive Audio Vocal Measurement in the Evaluation of Selective Mutism. Frontiers in psychiatry, 9443. https://doi.org/10.3389/fpsyt.2018.00443
Xu, Helen Y, et al. "Clinical Perspective on Passive Audio Vocal Measurement in the Evaluation of Selective Mutism." Frontiers in psychiatry vol. 9 (2018): 443. doi: https://doi.org/10.3389/fpsyt.2018.00443
Xu HY, Stroud J, Jozanovic RK, Clucas J, Son JJ, Koo B, Schwarz J, Klein A, Busman R, Milham MP. Clinical Perspective on Passive Audio Vocal Measurement in the Evaluation of Selective Mutism. Front Psychiatry. 2018 Sep 21;9:443. doi: 10.3389/fpsyt.2018.00443. eCollection 2018. PMID: 30298025; PMCID: PMC6161560.
Copy Download .nbib Format: NLM
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.

Cancer chemotherapy and pharmacology

Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T.
PMID: 32036412
Cancer Chemother Pharmacol. 2020 Mar;85(3):621-626. doi: 10.1007/s00280-020-04037-9. Epub 2020 Feb 08.

PURPOSE: CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize clinical activity. CC-486 300 mg daily, administered for 14 or 21 days of 28-day treatment cycles,...

Cite
Babiker HM, Milhem M, Aisner J, et al. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020;85(3):621-626doi: 10.1007/s00280-020-04037-9.
Babiker, H. M., Milhem, M., Aisner, J., Edenfield, W., Shepard, D., Savona, M., Iyer, S., Abdelrahim, M., Beach, C. L., Skikne, B., Laille, E., Tsai, K. T., & Ho, T. (2020). Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer chemotherapy and pharmacology, 85(3), 621-626. https://doi.org/10.1007/s00280-020-04037-9
Babiker, Hani M, et al. "Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer." Cancer chemotherapy and pharmacology vol. 85,3 (2020): 621-626. doi: https://doi.org/10.1007/s00280-020-04037-9
Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020 Mar;85(3):621-626. doi: 10.1007/s00280-020-04037-9. Epub 2020 Feb 08. PMID: 32036412; PMCID: PMC7036073.
Copy Download .nbib Format: NLM
Fibrous Proliferations in Posttransplant Kaposi Sarcoma.

The Journal of clinical and aesthetic dermatology

Adams KM, Milam P, Gru A, Kaffenberger BH.
PMID: 34804350
J Clin Aesthet Dermatol. 2021 Jun;14(6):18-20. Epub 2021 Jun 01.

Kaposi sarcoma (KS) is characterized by cutaneous lesions that are often papular and present variably depending on the stage of progression. We describe a patient with a fibroma-like nodule, a lesion not commonly associated with KS. Previously observed in...

Cite
Adams KM, Milam P, Gru A, et al. Fibrous Proliferations in Posttransplant Kaposi Sarcoma. J Clin Aesthet Dermatol. 2021;14(6):18-20
Adams, K. M., Milam, P., Gru, A., & Kaffenberger, B. H. (2021). Fibrous Proliferations in Posttransplant Kaposi Sarcoma. The Journal of clinical and aesthetic dermatology, 14(6), 18-20.
Adams, Kevin M, et al. "Fibrous Proliferations in Posttransplant Kaposi Sarcoma." The Journal of clinical and aesthetic dermatology vol. 14,6 (2021): 18-20.
Adams KM, Milam P, Gru A, Kaffenberger BH. Fibrous Proliferations in Posttransplant Kaposi Sarcoma. J Clin Aesthet Dermatol. 2021 Jun;14(6):18-20. Epub 2021 Jun 01. PMID: 34804350; PMCID: PMC8594533.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 169 entries